NASDAQ:APRI Apricus Biosciences Stock Forecast, Price & News Notice: This company has been marked as potentially delisted and may not be actively trading. Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Apricus Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $1.03 +0.13 (+14.44 %) (As of 11/27/2020 12:00 AM ET) Add Compare Share Today's Range$0.90Now: $1.03▼$1.0550-Day Range N/A52-Week Range$0.18Now: $1.03▼$3.34Volume2.89 million shsAverage Volume558,386 shsMarket Capitalization$29.02 millionP/E RatioN/ADividend YieldN/ABeta1.2 ProfileEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsSocial Media Seelos Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It focuses on development and advancement of novel therapeutics to address unmet medical needs for the benefit of patients with central nervous system disorders. Its portfolio includes late-stage clinical assets targeting psychiatric and movement disorders. The company is headquartered in New York, NY.Read More Beat the Market (BTM) Rank™ 0.0 Analyst's Opinion Consensus RatingThere is not enough analysis data for Apricus Biosciences. Previous Next 2.7 Community Rank Outperform VotesApricus Biosciences has received 230 “outperform” votes. (Add your “outperform” vote.)Underperform VotesApricus Biosciences has received 198 “underperform” votes. (Add your “underperform” vote.)Community SentimentApricus Biosciences has received 53.74% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Apricus Biosciences and other stocks. Vote “Outperform” if you believe APRI will outperform the S&P 500 over the long term. Vote “Underperform” if you believe APRI will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldApricus Biosciences does not currently pay a dividend.Dividend GrowthApricus Biosciences does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Apricus Biosciences insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 2.32% of the stock of Apricus Biosciences is held by insiders.Percentage Held by InstitutionsOnly 19.89% of the stock of Apricus Biosciences is held by institutions. Previous Next 0.0 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of Apricus Biosciences is -1.04, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Apricus Biosciences is -1.04, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioApricus Biosciences has a P/B Ratio of 3.55. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 0.0Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™0.54 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:APRI Previous Symbol CUSIPN/A CIK1017491 Webwww.apricusbio.com Phone(646) 293-2100EmployeesN/A Debt Debt-to-Equity RatioN/A Current Ratio3.86 Quick Ratio3.86Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$5.76 million Price / Sales5.04 Cash FlowN/A Price / Cash FlowN/A Book Value$0.29 per share Price / Book3.55Profitability EPS (Most Recent Fiscal Year)($0.99) Net Income$320,000.00 Net MarginsN/A Return on Equity-216.45% Return on Assets-153.13%Miscellaneous Outstanding Shares28,170,000Market Cap$29.02 million Next Earnings DateN/A OptionableNot Optionable Receive APRI News and Ratings via Email Sign-up to receive the latest news and ratings for APRI and its competitors with MarketBeat's FREE daily newsletter. Apricus Biosciences (NASDAQ:APRI) Frequently Asked Questions What stocks does MarketBeat like better than Apricus Biosciences? Wall Street analysts have given Apricus Biosciences a "N/A" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Apricus Biosciences wasn't one of them. MarketBeat thinks these five stocks may be even better buys.View MarketBeat's top stock picks here. How were Apricus Biosciences' earnings last quarter? Apricus Biosciences, Inc. (NASDAQ:APRI) released its quarterly earnings results on Wednesday, October, 31st. The company reported ($0.12) EPS for the quarter, topping the Thomson Reuters' consensus estimate of ($0.14) by $0.02. View Apricus Biosciences' earnings history. Who are some of Apricus Biosciences' key competitors? Some companies that are related to Apricus Biosciences include Enlivex Therapeutics (ENLV), Immunome (IMNM), Oncolytics Biotech (ONCY), Corvus Pharmaceuticals (CRVS), PhaseBio Pharmaceuticals (PHAS), Cyclerion Therapeutics (CYCN), Chembio Diagnostics (CEMI), DiaMedica Therapeutics (DMAC), ProPhase Labs (PRPH), Oramed Pharmaceuticals (ORMP), InflaRx (IFRX), Lipocine (LPCN), Palatin Technologies (PTN), BetterLife Pharma (PVOTF) and Corbus Pharmaceuticals (CRBP). View all competitors. What other stocks do shareholders of Apricus Biosciences own? Based on aggregate information from My MarketBeat watchlists, some companies that other Apricus Biosciences investors own include The Scotts Miracle-Gro (SMG), Pfizer (PFE), Grubhub (GRUB), The Boston Beer (SAM), Palatin Technologies (PTN), Synergy Pharmaceuticals (SGYP), Amicus Therapeutics (FOLD), Avon Products (AVP), Chesapeake Energy (CHKAQ) and Novavax (NVAX). Who are Apricus Biosciences' key executives? Apricus Biosciences' management team includes the following people: Raj Mehra, Chairman, President, CEO & CFOWarren W. Wasiewski, Chief Medical OfficerJessica Kardish, Head-Clinical OperationsTim Whitaker, Head-Research & DevelopmentAnthony Marciano, Head-Corporate Communications What is Apricus Biosciences' stock symbol? Apricus Biosciences trades on the NASDAQ under the ticker symbol "APRI." What is Apricus Biosciences' stock price today? One share of APRI stock can currently be purchased for approximately $1.03. How big of a company is Apricus Biosciences? Apricus Biosciences has a market capitalization of $29.02 million and generates $5.76 million in revenue each year. The company earns $320,000.00 in net income (profit) each year or ($0.99) on an earnings per share basis. What is Apricus Biosciences' official website? The official website for Apricus Biosciences is www.apricusbio.com. How can I contact Apricus Biosciences? Apricus Biosciences' mailing address is 11975 EL CAMINO REAL SUITE 300, SAN DIEGO CA, 92130. The company can be reached via phone at (646) 293-2100 or via email at [email protected] This page was last updated on 11/28/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
